-

SpineGuard Strengthens Its Intellectual Property With a New Patent Granted in the USA

  • Perfecting the ‘real time’ characteristic of the DSG technology
  • Protection until 2035

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today the grant of a new patent in the United States, following grants in China, Japan, Mexico, France, Israel, Russia and Singapore. This patent discloses certain characteristics of the DSG technology that optimize its real time implementation.

Stéphane Bette, Deputy CEO and cofounder of SpineGuard, said: “Since its foundation, SpineGuard has been developing, deploying and fine-tuning its tissue electrical conductivity local measurement technology for securing and streamlining the placement of implants in bone, manually or with robotic assistance, while decreasing the dangerous systematic reliance on X-ray imaging. Our intellectual property portfolio keeps expanding and the validated invention perfects our technology and affirms its uniqueness in the long term, a key asset in the context of our strategic discussions with potential industry partners. The grant of this major patent in the United States coincides with the ongoing strengthening of our commercial organization in the largest market of our sector.

Since its inception, SpineGuard develops and maintains a significant IP portfolio now reaching 15 patent families totaling 78 patents and applications as well as 3 trademarks, in the major geographies such as Europe, USA and China.

SpineGuard is focused on the following priorities while striving to remain close to breakeven:

  1. Boost commercial activities with the launch of the DSG-Connect visual interface.
  2. Implement DSG technology in ortho-robotics through the deployment of AI algorithms, new scientific evidence, and additional patents.
  3. Intensify the collaboration with ConfiDent ABC for the dental application and co-develop a new generation of products embedding the DSG technology.
  4. Affirm the company’s technological shift and sign strategic partnerships in particular for the use of DSG technology in the robotic field.

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 85,000 surgical procedures worldwide. Seventeen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu

SpineGuard

BOURSE:ALSGD

Release Versions

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu

More News From SpineGuard

SpineGuard: Official Launch of Three New PediGuard® Models During the Annual Scoliosis Meeting in China

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announced the official launch of the newly cleared Curved and XS PediGuard models, in Nanjing (China), during the 2026 Chinese Scoliosis Annual Meeting in conjunction with French Spine Society. PediGuard has been highlighted by Profe...

SpineGuard and Omnia Medical Complete US Asset Transfer and Enter Exclusive Distribution Agreement for PediGuard®

MORGANTOWN, W. Va. & BOULDER, Colo. & PARIS--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company specializing in Dynamic Surgical Guidance (DSG®) technology to enhance the safety and efficiency of bone implant placement, and Omnia Medical, an orthopedic implant company focused on innovative spine and sacroiliac solutions, today announced the completion of the transfer of SpineGuard Inc assets and the execution of an exclusive distribution U.S. distribution...

SpineGuard Announces Full-Year 2025 Financial Results, First Quarter 2026 Sales, and the Set-Up of a Bond Financing

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, today announces its full-year 2025 financial results for the year ended December 31, 2025, as approved by the Board of Directors on April 07, 2026, its first quarter 2026 sales, as well as the completion of a bond financing of up to €1 million. 2025 Financia...
Back to Newsroom